MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.

@article{Brischwein2006MT110AN,
  title={MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.},
  author={Klaus Brischwein and Bernd Schlereth and Benjamin Guller and Carola Steiger and Andreas Wolf and Ralf Lutterbuese and Sonja Offner and Mathias Locher and Thomas Urbig and Tobias Raum and Petra Kleindienst and Pauline Wimberger and Rainer Kimmig and Iduna Fichtner and Peter Kufer and Robert R Hofmeister and A Marques Joppert Da Silva and P Atricka . Baeuerle},
  journal={Molecular immunology},
  year={2006},
  volume={43 8},
  pages={
          1129-43
        }
}
We have developed a novel single-chain Ep-CAM-/CD3-bispecific single-chain antibody construct designated MT110. MT110 redirected unstimulated human peripheral T cells to induce the specific lysis of every Ep-CAM-expressing tumor cell line tested. MT110 induced a costimulation independent polyclonal activation of CD4- and CD8-positive T cells as seen by de novo expression of CD69 and CD25, and secretion of interferon gamma, tumor necrosis factor alpha, and interleukins 2, 4 and 10. CD8-positive… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 100 CITATIONS

Similar Papers

Loading similar papers…